We recently reported that GPR133 is expressed in glioblastoma (GBM), the most common brain malignancy, while normal brain tissue has no baseline expression.6,7 Using patient-derived cultures and xenografts of GBM, we showed that knockdown of GPR133 impairs tumor initiation in vitro and in vivo, suggesting GPR133 supports tumor growth.6 Consistent with this hypothesis, increased GPR133 mRNA transcript correlates with reduced patient survival in the TCGA database.6 These findings suggest GPR133 represents a novel therapeutic target in GBM. Here, ADGRD1 is linked to neoplasm.